Approval · Notice of Compliance 6209 · 2005
SUBUTEX: Notice of Compliance 6209
Issued January 21, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6209
- Date
- January 21, 2005
- Company
- Schering Canada Inc.
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority
- Therapeutic class
- Opiate agonist/antagonist: for substitution treatment in opioid drug dependence in adults through subutex national education program
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUBUTEX | 02242962 | — |
| SUBUTEX | 02242963 | — |
| SUBUTEX | 02242964 | — |
Medicinal ingredients
- BUPRENORPHINE HYDROCHLORIDE 0.4 MG per TAB
- BUPRENORPHINE HYDROCHLORIDE 2 MG per TAB
- BUPRENORPHINE HYDROCHLORIDE 8 MG per TAB